{"id":401506,"date":"2020-12-17T01:03:17","date_gmt":"2020-12-17T06:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=401506"},"modified":"2020-12-17T01:03:17","modified_gmt":"2020-12-17T06:03:17","slug":"novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/","title":{"rendered":"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        \n      <\/p>\n<p align=\"center\">\n        <strong>Novadiscovery announces key collaboration with Janssen France to provide <em>in silico <\/em>based decision support for clinical development<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Lyon, France \u2013 17 December 2020:<\/strong> Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jink\u014d\u00ae, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide <em>in silico<\/em> based decision support for its clinical development pipeline.<\/p>\n<p align=\"justify\">Novadiscovery is committed to working with forward-looking industry leaders to improve R&amp;D productivity and maximize patient outcomes through disease modeling and simulation, ahead of human trials.<\/p>\n<p align=\"justify\">Regulatory agencies in the US and Europe are working to provide a framework for the expanded use of model-informed drug development (MiDD) to improve clinical trial efficiency and increase the probability of regulatory success.<\/p>\n<p align=\"justify\">\n        <strong>Fran\u00e7ois-Henri Boissel, CEO, Novadiscovery, commented:<\/strong> \u201c<em>We are proud to have been selected by a leading pharmaceutical company to help provide answers to key clinical development questions in the future of healthcare. We are excited to join with Janssen France as it adopts this new technology and we envisage a long and productive collaboration.\u201d <\/em><\/p>\n<p align=\"justify\">\n        <strong>Philippe Bonnard, Medical Director Oncology, Janssen France, highlighted:<\/strong><br \/>\n        <em> \u201cOur strategic goal is to transform drug R&amp;D using innovative digital technologies. In this collaboration with Nova, we look forward to realizing the potential of in silico technology to help us deliver higher quality compounds more effectively.\u201d<\/em>\n      <\/p>\n<p align=\"center\">\n        <strong>Ends<\/strong>\n      <\/p>\n<p>\n        <strong>For more information, please contact:<\/strong>\n      <\/p>\n<p>\n        <strong>Novadiscovery<\/strong><br \/>\n        <br \/> Fran\u00e7ois-Henri Boissel, Chief Executive Officer<br \/>Email: <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2pEubUB8KpT5kL71PJajONuXO7j1mJ4YU19oLmmGJAaJfbbuTOwC5VbyUQSl4BMGfaJcUFJOEQcEMiZ-Lt8rM7ET2iifJTpZgbylQXN97DNyY-D5wUaKeq_Uep0S5f1I\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">contact@novadiscovery.com<\/a><\/u><\/p>\n<p>\n        <strong>Consilium Strategic Communications <\/strong><br \/>\n        <br \/>Sukaina Virji, Melissa Gardiner, Carina Jurs<br \/>Email: <u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ROvXeYUjRIeillR-gsFNoJGfFS2AvwEe2buxjIW_Z9gXRIhfWy89CRk7sbfUuNqlzlTpF7JXpkD6yOL9w1oWBb7bwZASazUwimDKVfQR3WSFY7KEoRHmUl1CgLMxiWNkebZ1mIN6BxtH8Qg3pIaNlA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">novadiscovery@consilium-comms.com<\/a><\/u><\/p>\n<p align=\"justify\">\n        <strong>About Novadiscovery<\/strong>\n      <\/p>\n<p align=\"justify\">Novadiscovery is a leading health tech company using <em>in silico<\/em> clinical trials to predict drug efficacy and optimize clinical trial development. The Company aims to improve R&amp;D productivity and maximize patient outcomes by predicting the clinical benefit of a potential new drug candidate through computer simulation, ahead of human trials.<\/p>\n<p align=\"justify\">Novadiscovery\u2019s innovative approach leverages disease modeling and simulation expertise accumulated over the past decade and combines mathematical models of diseases and potential new treatments with virtual patients in its integrated clinical trial simulation platform, Jink\u014d\u00ae.<\/p>\n<p align=\"justify\">Novadiscovery is headquartered in Lyon, France and has a team of around 30 scientists, engineers &amp; clinicians who work at the interface of biology, pharmacology, mathematics &amp; computer science.<\/p>\n<p align=\"justify\">For more information, please visit https:\/\/www.novadiscovery.com and follow us on Twitter @novadiscovery and linkedin.com\/company\/novadiscovery<\/p>\n<p>\n        \n      <\/p>\n<p align=\"justify\">Version fran\u00e7aise:<\/p>\n<p align=\"center\">\n        <strong>Novadiscovery annonce une collaboration strat\u00e9gique avec Janssen France pour l&#8217;acc\u00e9l\u00e9ration de son d\u00e9veloppement clinique gr\u00e2ce aux essais <em>in silico<\/em><\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Lyon, France &#8211; [XX] d\u00e9cembre 2020:<\/strong> Novadiscovery, soci\u00e9t\u00e9 leader dans le domaine des technologies de la sant\u00e9, offrant une plateforme de simulation informatique d\u2019essais cliniques, de pr\u00e9diction de l&#8217;efficacit\u00e9 des m\u00e9dicaments et d\u2019optimisation du d\u00e9veloppement d&#8217;essais cliniques, annonce aujourd&#8217;hui qu&#8217;elle est entr\u00e9e dans une collaboration avec Janssen France pour fournir une aide \u00e0 la d\u00e9cision <em>in silico<\/em> dans le cadre du d\u00e9veloppement clinique.<\/p>\n<p align=\"justify\">Novadiscovery s&#8217;est engag\u00e9e \u00e0 travailler avec des leaders de l&#8217;industrie tourn\u00e9s vers l&#8217;avenir pour am\u00e9liorer, mod\u00e9liser et simuler des maladies, avant de conduire les essais chez l&#8217;homme. Novadiscovery s\u2019appuie notamment sur une plateforme de simulation d&#8217;essais cliniques, Jink\u014d\u00ae.<\/p>\n<p align=\"justify\">Les autorit\u00e9s de sant\u00e9 aux \u00c9tats-Unis et en Europe travaillent \u00e0 la mise en \u0153uvre d\u2019un cadre pour la mise en place d\u2019essais cliniques <em>in silico<\/em> (ou Model-informed Drug Development MiDD) afin d&#8217;am\u00e9liorer l&#8217;efficacit\u00e9 du d\u00e9veloppement clinique et d&#8217;augmenter la probabilit\u00e9 de succ\u00e8s r\u00e9glementaires.<\/p>\n<p align=\"justify\">\n        <strong>Fran\u00e7ois-Henri Boissel, PDG de Novadiscovery,<\/strong> a d\u00e9clar\u00e9 : \u00ab Nous sommes fiers d&#8217;avoir \u00e9t\u00e9 s\u00e9lectionn\u00e9s par une entreprise pharmaceutique d\u2019envergure mondiale, qui s\u2019attache \u00e0 travailler \u00e0 l&#8217;avenir des soins de sant\u00e9 pour apporter des r\u00e9ponses aux questions cl\u00e9s du d\u00e9veloppement clinique. Nous sommes ravis de nous joindre \u00e0 Janssen France dans leur adoption de nouvelles technologies et nous envisageons une collaboration longue et productive. \u00bb<\/p>\n<p align=\"justify\">\n        <strong>Philippe Bonnard, Directeur M\u00e9dical Oncologie chez Janssen France,<\/strong> a affirm\u00e9 : \u00ab Notre objectif strat\u00e9gique est de faire \u00e9voluer la R&amp;D en utilisant des technologies num\u00e9riques innovantes. Dans le cadre de cette collaboration avec Novadiscovery, nous sommes impatients de pouvoir nous appuyer sur le potentiel de la technologie <em>in silico <\/em>pour simuler les effets de nos mol\u00e9cules sur une population de patients virtuelle, tout en garantissant la rigueur scientifique, la transparence et la tra\u00e7abilit\u00e9 totale pour r\u00e9pondre aux crit\u00e8res des agences de r\u00e9glementation de sant\u00e9.\u201d<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml-eu.globenewswire.com\/release\/track\/e07d75de-330d-4e34-9856-096dc006cfc6\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development Lyon, France \u2013 17 December 2020: Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jink\u014d\u00ae, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with forward-looking industry leaders to improve R&amp;D productivity and maximize patient outcomes through disease modeling and simulation, ahead of human trials. Regulatory agencies in the US and Europe are working to provide a framework for the expanded use of model-informed drug development (MiDD) to improve &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-401506","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development Lyon, France \u2013 17 December 2020: Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jink\u014d\u00ae, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with forward-looking industry leaders to improve R&amp;D productivity and maximize patient outcomes through disease modeling and simulation, ahead of human trials. Regulatory agencies in the US and Europe are working to provide a framework for the expanded use of model-informed drug development (MiDD) to improve &hellip; Continue reading &quot;Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-17T06:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development\",\"datePublished\":\"2020-12-17T06:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/\"},\"wordCount\":764,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/\",\"name\":\"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz\",\"datePublished\":\"2020-12-17T06:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/","og_locale":"en_US","og_type":"article","og_title":"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development - Market Newsdesk","og_description":"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development Lyon, France \u2013 17 December 2020: Novadiscovery, a leading health tech company offering a best-in-class clinical trial simulation platform, Jink\u014d\u00ae, to predict drug efficacy and optimize clinical trial development, today announces that it has entered into a collaboration with Janssen France to provide in silico based decision support for its clinical development pipeline. Novadiscovery is committed to working with forward-looking industry leaders to improve R&amp;D productivity and maximize patient outcomes through disease modeling and simulation, ahead of human trials. Regulatory agencies in the US and Europe are working to provide a framework for the expanded use of model-informed drug development (MiDD) to improve &hellip; Continue reading \"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-17T06:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development","datePublished":"2020-12-17T06:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/"},"wordCount":764,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/","name":"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz","datePublished":"2020-12-17T06:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDQ0NjM0MiM0MDA4Mzk0NjYjNzAwMDEyMDcz"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/novadiscovery-announces-key-collaboration-with-janssen-france-to-provide-in-silico-based-decision-support-for-clinical-development\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Novadiscovery announces key collaboration with Janssen France to provide in silico based decision support for clinical development"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=401506"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/401506\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=401506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=401506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=401506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}